DREAMS is committed TO REDUCING HIV among adolescent girls and young women
Why Adolescent Girls and Young women?
DREAMS is committed to achieving a 40 percent reduction in new HIV/AIDS infections among adolescent girls and young women in the highest-burden countries by the end of 2017.
Despite considerable progress in the overall global HIV/AIDS response, gender and age disparities in high-HIV burden sub-Saharan African countries remain almost unchanged. Girls and young women account for 74 percent of new HIV infections among adolescents in sub-Saharan Africa. The 10 DREAMS countries (Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe) account for more than half of all the new HIV infections that occurred among adolescent girls and young women globally in 2015.
This must change.
Many adolescent girls and young women lack a full range of opportunities and are too often devalued because of gender bias, leading them to be seen as unworthy of investment or protection. Social isolation, economic disadvantage, discriminatory cultural norms, orphanhood, gender-based violence, and school drop-out all contribute to girls' vulnerability to HIV.
DREAMS has the potential to change how we work together to ensure an AIDS-free future for girls and women.
DREAMS is about multiple solutions surrounding one problem. With support from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences, and ViiV Healthcare, DREAMS is delivering a core package that combines evidence-based approaches that go beyond the health sector, addressing the structural drivers that directly and indirectly increase girls' HIV risk, including poverty, gender inequality, sexual violence, and a lack of education.
Where We Work
DREAMS is focused on implementing evidence-informed and innovative approaches to empower adolescent girls and women in districts of 10 sub-Saharan African countries that have the highest burden of HIV infection.